Tomoyuki Homma

22 papers receiving 668 citations

Peers

Tomoyuki Homma
Comparison fields: 5 of 92
  • Molecular Biology 269
  • Cardiology and Cardiovascular Medicine 128
  • Nephrology 115
  • Endocrinology, Diabetes and Metabolism 109
  • Pharmacology 100
Replace Rachel M. Golonka with:
Rachel M. Golonka United States
Bettina Schneider Germany
S. M. A. Abidi India
Guangwei Yang China
Hua Yu China
Linying Zhou China
Guizhen Wang China
Chitta R. Dey United States
Zheng Ma China
Tomoyuki Homma relative to Rachel M. Golonka United States Rachel M. Golonka's profile →
Citations per field
00.5×9.6×
Rachel M. Golonka · 1×
Citations per year

Countries citing papers authored by Tomoyuki Homma

Since Specialization
Citations

This map shows the geographic impact of Tomoyuki Homma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoyuki Homma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoyuki Homma more than expected).

Fields of papers citing papers by Tomoyuki Homma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoyuki Homma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoyuki Homma. The network helps show where Tomoyuki Homma may publish in the future.

Co-authorship network of co-authors of Tomoyuki Homma

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoyuki Homma. A scholar is included among the top collaborators of Tomoyuki Homma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoyuki Homma. Tomoyuki Homma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 11
3 11
4 2
5 5
6 22
7 56
8 73
9 7
10 6
11 8
12 8
13 6
14 3
15 0
16 126
17 51
18 143
19
Serum antibodies to human T-cell leukaemia virus type I in different ethnic groups and in non-human primates in South Africa.
24
20
HTLV and immunosuppression.
6

About Tomoyuki Homma

Tomoyuki Homma is a scholar working on Molecular Medicine, Infectious Diseases and Animal Science and Zoology, having authored 24 papers that have together received 690 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (4 papers), Influenza Virus Research Studies (4 papers) and Respiratory viral infections research (4 papers). The work is most often cited by research in Nephrology (115 citations), Molecular Medicine (56 citations) and Endocrinology, Diabetes and Metabolism (109 citations). Tomoyuki Homma has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Yoshinobu Kaneko, Choowong Auesukaree, Satoshi Harashima, Alan D. Glick, Yoshiyuki Yoshida, Iekuni Ichikawa, Agnes B. Fogo, Kevin D. Burns, R. C. Harris and Masahiro Shirakawa. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026